Beyond analysts' top -and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) closed at $99.52 in the latest trading session, marking a +1.18% move from the prior day.
Cardinal Health's recent dividend raise (about 1%) reflects growth pressure ahead. With a ~13x P/E, valuation seems reasonable on the surface. However, when adjusted for growth, the current valuation points to an unfavorable return profile.
Cardinal Health (CAH) reachead $100.83 at the closing of the latest trading day, reflecting a +0.57% change compared to its last close.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In the most recent trading session, Cardinal Health (CAH) closed at $96.71, indicating a +0.91% shift from the previous trading day.
In the closing of the recent trading day, Cardinal Health (CAH) stood at $95.84, denoting a +0.44% change from the preceding trading day.
FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.
Cardinal Health (CAH) closed at $95.97 in the latest trading session, marking a +0.59% move from the prior day.
Cardinal Health (CAH) concluded the recent trading session at $93.74, signifying a -0.38% move from its prior day's close.
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.